1. Home
  2. BYFC vs GANX Comparison

BYFC vs GANX Comparison

Compare BYFC & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BYFC
  • GANX
  • Stock Information
  • Founded
  • BYFC 1946
  • GANX 2017
  • Country
  • BYFC United States
  • GANX United States
  • Employees
  • BYFC N/A
  • GANX N/A
  • Industry
  • BYFC Savings Institutions
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BYFC Finance
  • GANX Health Care
  • Exchange
  • BYFC Nasdaq
  • GANX Nasdaq
  • Market Cap
  • BYFC 70.3M
  • GANX 69.0M
  • IPO Year
  • BYFC 1996
  • GANX 2021
  • Fundamental
  • Price
  • BYFC $7.34
  • GANX $1.65
  • Analyst Decision
  • BYFC
  • GANX Strong Buy
  • Analyst Count
  • BYFC 0
  • GANX 5
  • Target Price
  • BYFC N/A
  • GANX $8.20
  • AVG Volume (30 Days)
  • BYFC 1.7K
  • GANX 614.3K
  • Earning Date
  • BYFC 10-28-2025
  • GANX 11-13-2025
  • Dividend Yield
  • BYFC N/A
  • GANX N/A
  • EPS Growth
  • BYFC N/A
  • GANX N/A
  • EPS
  • BYFC N/A
  • GANX N/A
  • Revenue
  • BYFC $33,412,000.00
  • GANX N/A
  • Revenue This Year
  • BYFC N/A
  • GANX N/A
  • Revenue Next Year
  • BYFC N/A
  • GANX N/A
  • P/E Ratio
  • BYFC N/A
  • GANX N/A
  • Revenue Growth
  • BYFC N/A
  • GANX N/A
  • 52 Week Low
  • BYFC $5.71
  • GANX $1.36
  • 52 Week High
  • BYFC $9.46
  • GANX $3.19
  • Technical
  • Relative Strength Index (RSI)
  • BYFC 37.50
  • GANX 43.33
  • Support Level
  • BYFC $7.26
  • GANX $1.55
  • Resistance Level
  • BYFC $7.50
  • GANX $1.78
  • Average True Range (ATR)
  • BYFC 0.11
  • GANX 0.13
  • MACD
  • BYFC -0.05
  • GANX -0.03
  • Stochastic Oscillator
  • BYFC 10.35
  • GANX 18.00

About BYFC Broadway Financial Corporation

Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank's business consists of deposits from the general public and using such deposits, together with borrowings and other funds, to make mortgage loans secured by residential properties and commercial real estate. Its deposits consist of passbook savings accounts, checking accounts, and negotiable order of withdrawal accounts, money market accounts and fixed-term certificates of deposit. The revenue is derived from interest income on loans and investments.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: